Vascular Biogenics Ltd. (NASDAQ:VBLT) went down by -12.55% from its latest closing price compared to the recent 1-year high of $3.09. The company’s stock price has collected -12.55% of loss in the last five trading sessions. Press Release reported 17 hours ago that VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
Is It Worth Investing in Vascular Biogenics Ltd. (NASDAQ :VBLT) Right Now?
Plus, the 36-month beta value for VBLT is at 0.90. Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for Vascular Biogenics Ltd. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $5.00. VBLT currently public float of 37.18M and currently shorts hold a 5.02% ratio of that float. Today, the average trading volume of VBLT was 514.75K shares.
VBLT’s Market Performance
VBLT stocks went down by -12.55% for the week, with a monthly drop of -12.89% and a quarterly performance of 84.30%, while its annual performance rate touched 53.79%. The volatility ratio for the week stands at 9.54% while the volatility levels for the past 30 days are set at 10.98% for Vascular Biogenics Ltd.. The simple moving average for the period of the last 20 days is -11.53% for VBLT stocks with a simple moving average of 49.68% for the last 200 days.
Analysts’ Opinion of VBLT
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see VBLT reach a price target of $3, previously predicting the price at $25. The rating they have provided for VBLT stocks is “Neutral” according to the report published on March 09th, 2018.
VBLT Trading at -0.05% from the 50-Day Moving Average
After a stumble in the market that brought VBLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.83% of loss for the given period.
Volatility was left at 10.98%, however, over the last 30 days, the volatility rate increased by 9.54%, as shares sank -17.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +53.79% upper at present.
During the last 5 trading sessions, VBLT fell by -12.55%, which changed the moving average for the period of 200-days by +36.81% in comparison to the 20-day moving average, which settled at $2.50. In addition, Vascular Biogenics Ltd. saw 17.99% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for VBLT
Current profitability levels for the company are sitting at:
- -4041.81 for the present operating margin
- -230.60 for the gross margin
The net margin for Vascular Biogenics Ltd. stands at -3462.10. The total capital return value is set at -49.45, while invested capital returns managed to touch -42.72. Equity return is now at value -61.80, with -47.20 for asset returns.
Based on Vascular Biogenics Ltd. (VBLT), the company’s capital structure generated 8.21 points at debt to equity in total, while total debt to capital is 7.58. Total debt to assets is 6.05, with long-term debt to equity ratio resting at 6.05. Finally, the long-term debt to capital ratio is 5.59.
When we switch over and look at the enterprise to sales, we see a ratio of 16.84, with the company’s debt to enterprise value settled at 0.31. The receivables turnover for the company is 2.28 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.33.